22 August 2011
Altered serum creatine kinase level and cardiac function in ischemia-reperfusion injury during percutaneous coronary intervention
Yi LuoABCDEFG, Yi-Zhi PanABCDE, Chong ZengABCD, Guang-lian LiABCD, Xiao-ming LeiABCD, Zhen LiuABCD, Shu-Feng ZhouABCDEFGDOI: 10.12659/MSM.881932
Med Sci Monit 2011; 17(9): CR474-479
Abstract
Background: Myocardial ischemia-reperfusion injury (MIRI) resulting from primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is considered harmful to the patient, but its clinical significance remains unclear. This study explored the relationship of cardiac function examined by echocardiography and serum creatine kinase (CK) and CK-MB levels with MIRI in a cohort of Chinese AMI patients.
Material/Methods: We retrospectively analysed the clinical and angiographic data in 228 AMI patients in whom the infarct-related artery (IRA) was successfully recanalized by primary PCI. Cardiac function was evaluated by use of echocardiography before discharge from hospital.
Results: The in-hospital mortality rate in the MIRI group was 13.4% (16/119), which was significantly higher than the 4.6% (5/109) mortality rate in the non-MIRI group (P=0.021). The median of peak serum CK level was remarkably lower in the suppression-type MIRI group than in the non-MIRI group. There were no significant differences in the peak serum CK or CK-MB levels between the irritation-type MIRI group and the non-MIRI group. The peak CK and CK-MB levels were significantly higher in the no-reflow-type MIRI group than in the non-MIRI group. Left ventricular ejection fraction in the no-reflow-type MIRI group was significantly lower than in the non-MIRI group; left ventricular end-diastolic volume was significantly higher than in the irritation-type MIRI subgroup; and left ventricular end-systolic volume was greater than that in non-MIRI group and suppression-type MIRI group.
Conclusions: MIRI (especially the no-reflow type) may lead to acute hemodynamic disorders and increase the mortality rate. However, suppression- and irritation-type MIRI may imply the existence of surviving myocardium.
Keywords: Heart Function Tests, Creatine Kinase, MB Form - blood, Creatine Kinase - blood, Angioplasty, Balloon, Coronary, Aged, 80 and over, Myocardial Reperfusion Injury - ultrasonography, Myocardium - pathology
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study ...Med Sci Monit In Press; DOI: 10.12659/MSM.947703
Clinical Research
Comparative Analysis of Laser Therapies for Striae Distensae: Fractional CO₂ vs Combined Q-Switch Nd:YAGMed Sci Monit In Press; DOI: 10.12659/MSM.947464
Database Analysis
Utility of Central Venous Oxygen Saturation Gradient in Predicting Mortality in Dialysis with Catheter AccessMed Sci Monit In Press; DOI: 10.12659/MSM.947298
Clinical Research
Intraoperative Renal Near-Infrared Spectroscopy Monitoring as a Predictor of Renal Outcomes in Cardiac SurgeryMed Sci Monit In Press; DOI: 10.12659/MSM.947462
Most Viewed Current Articles
17 Jan 2024 : Review article 7,094,149
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,321
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,595
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,787
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912